Valuation: Genmab A/S

Market Cap 119B 18.45B 15.96B 14.9B 13.67B 25.71B 1,756B 26.12B 175B 68.63B 880B 69.28B 67.77B 2,910B P/E 2026 *
25.5x
P/E 2027 * 18x
Enterprise Value 139B 21.47B 18.57B 17.34B 15.91B 29.92B 2,043B 30.4B 203B 79.87B 1,024B 80.63B 78.86B 3,386B EV / Sales 2026 *
4.8x
EV / Sales 2027 * 3.87x
Free-Float
95.41%
Yield 2026 *
-
Yield 2027 * -
1 day+6.50%
1 week+7.56%
Current month+7.56%
1 month+5.66%
3 months+21.78%
6 months+2.09%
Current year-1.38%
1 week 1,819.5
Extreme 1819.5
2,066
1 month 1,819.5
Extreme 1819.5
2,066
Current year 1,512
Extreme 1512
2,257
1 year 1,337
Extreme 1337
2,257
3 years 1,157
Extreme 1157
2,710
5 years 1,157
Extreme 1157
3,327
10 years 786.2
Extreme 786.2
3,327
Manager TitleAgeSince
Chief Executive Officer 65 2010-05-31
Director of Finance/CFO 48 2020-02-29
Chief Tech/Sci/R&D Officer - 2024-08-15
Director TitleAgeSince
Director/Board Member 75 2003-10-31
Director/Board Member 58 2014-12-31
Director/Board Member 75 2014-12-31
Date Insider Type Main position Quantity % Market Cap.
12/1/25 Fiscal year

Director

189 0.0003%
12/1/25 Fiscal year

Director

189 0.0003%
12/1/25 Fiscal year

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+6.50%+7.56%+44.65%-21.73% 18.45B
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
+2.12%+3.54%+433.80%+218.84% 12.38B
Average +3.67%+10.87%+91.98%+208.74% 27.59B
Weighted average by Cap. +4.26%+12.67%+67.88%+170.73%

Financials

2026 *2027 *
Net sales 28.95B 4.48B 3.87B 3.61B 3.32B 6.24B 426B 6.34B 42.41B 16.65B 213B 16.81B 16.44B 706B 33.63B 5.2B 4.5B 4.2B 3.85B 7.25B 495B 7.36B 49.27B 19.34B 248B 19.52B 19.1B 820B
Net income 4.92B 761M 658M 614M 564M 1.06B 72.38B 1.08B 7.21B 2.83B 36.28B 2.86B 2.79B 120B 7.18B 1.11B 960M 896M 822M 1.55B 106B 1.57B 10.51B 4.13B 52.92B 4.17B 4.07B 175B
Net Debt 19.54B 3.02B 2.61B 2.44B 2.24B 4.21B 288B 4.28B 28.63B 11.24B 144B 11.35B 11.1B 476B 10.72B 1.66B 1.43B 1.34B 1.23B 2.31B 158B 2.35B 15.71B 6.17B 79.08B 6.23B 6.09B 261B
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,119
Date Price Change Volume
26-08-07 DKK 1,999.00 +6.50% 316,139
26-08-06 DKK 1,877.00 -0.79% 90,714
26-08-05 DKK 1,892.00 +0.75% 94,097
26-08-04 DKK 1,878.00 +1.73% 86,208
26-08-03 DKK 1,846.00 -0.67% 93,363
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
1,999.00DKK
Average target price
2,406.59DKK
Spread / Average Target
+20.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GMAB Stock